{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T06:45:50Z","timestamp":1782456350937,"version":"3.54.5"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There has been an annual rise in the incidence of primary membranous nephropathy (PMN), a common pathological type of nephrotic syndrome (NS). Obinutuzumab is a humanised, glycosylated, type II anti-CD20 monoclonal antibody. Characterised by its enhanced B-cell depletion capability compared with rituximab (RTX), obinutuzumab has demonstrated promising efficacy in the treatment of membranous nephropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to investigate the efficacy and safety of obinutuzumab in treating various subtypes of PMN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 94 PMN patients with NS were enrolled in this study. Based on their treatment history before receiving obinutuzumab, the patients were categorised into the Initial therapy group (group A, n=32), the Refractory group (group B, n=32), and the Remedial therapy group (group C, n=30). The efficacy and safety of obinutuzumab treatment after a 24-month follow-up period were observed and analysed in each group. The primary endpoint was the clinical remission rate (complete remission + partial remission) at 24 months, and the secondary endpoints were treatment safety and the incidence of treatment-emergent adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Following 24 months of obinutuzumab therapy, 95.74% (90\/94) of the PMN patients achieved clinical remission, with 28.72% (27\/94) reaching complete remission (CR) and 67.02% (63\/94) achieving partial remission (PR). The Initial therapy group (group A) achieved a 100% (32\/32) clinical remission rate: 37.5% (12\/32) attained CR, and 62.5% (20\/32) attained PR. The Refractory group (group B) achieved a 96.88% (31\/32) clinical remission rate: 25% (8\/32) attained CR, and 71.88% (23\/32) attained PR. The Remedial therapy group (group C) achieved a 90% (27\/30) clinical remission rate: 23.33% (7\/30) attained CR, and 66.67% (20\/30) attained PR. All 63 anti-PLA2R antibody-positive (&amp;gt;20 U\/mL) patients and 16 anti-PLA2R antibody negativity but no immunological remission (2\u201320 U\/mL) patients demonstrated declining antibody levels following obinutuzumab therapy, and 68.4% (54\/79) attained complete immunological remission (&amp;lt;2 U\/mL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Obinutuzumab demonstrates high clinical remission rates and acceptable safety in PMN patients, with good efficacy even in refractory and RTX-resistant patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1825745","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:46:39Z","timestamp":1782452799000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of obinutuzumab in patients with primary membranous nephropathy: a focus on refractory and rituximab-resistant patients"],"prefix":"10.3389","volume":"17","author":[{"given":"Qi","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxiang","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1324804","article-title":"Anti-PLA2R1 antibodies containing sera induce in vitro cytotoxicity mediated by complement activation","volume":"2019","author":"Lateb","year":"2019","journal-title":"J Immunol Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.02.1033","article-title":"Complement pathways in membranous nephropathy: complex and multifactorial","volume":"5","author":"Brglez","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/bf00866338","article-title":"Prognosis of untreated patients with idiopathic membranous nephropathy","volume":"329","author":"Schieppati","year":"1993","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s0270-9295(03)00049-4","article-title":"Diagnosis and natural course of membranous nephropathy","volume":"23","author":"Glassock","year":"2003","journal-title":"Semin Nephrol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1681\/asn.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/nejmoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1172\/jci85265","article-title":"Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy","volume":"126","author":"Tomas","year":"2016","journal-title":"J Clin Invest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.01460217","article-title":"Circulating antibodies against thrombospondin type-I domain-containing 7A in Chinese patients with idiopathic membranous nephropathy","volume":"12","author":"Wang","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.09.005","article-title":"Differential diagnosis of membranous nephropathy with autoantibodies to phospholipase A2 receptor 1","volume":"13","author":"Schlumberger","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"2024 clinical practice guideline for the management of LUPUS NEPHRITIS","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy","volume":"28","author":"van den Brand","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.12.011","article-title":"Novel treatments paradigms: membranous nephropathy","volume":"8","author":"Rojas-Rivera","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1159\/000437287","article-title":"Management of membranous nephropathy in Western countries","volume":"1","author":"Alfaadhel","year":"2015","journal-title":"Kidney Dis (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-585976","article-title":"Human T-follicular helper and T-follicular regulatory cell maintenance is independent of germinal centers","volume":"124","author":"Wallin","year":"2014","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/01.asn.0000071511.35221.b3","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859419","article-title":"Advances in the management of primary membranous nephropathy and rituximab-refractory membranous nephropathy","volume":"13","author":"Teisseyre","year":"2022","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1586\/eci.12.26","article-title":"Rituximab: emerging treatment strategies of immune-mediated glomerular disease","volume":"8","author":"Kattah","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12882-022-02761-3","article-title":"Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases","volume":"23","author":"Hudson","year":"2022","journal-title":"BMC Nephrol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.0000000000000288","article-title":"Obinutuzumab in frequently relapsing and steroid-dependent nephrotic syndrome in children","volume":"18","author":"Dossier","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae139","article-title":"The efficacy and safety of rituximab with or without glucocorticoid in inducing remission of MCD with different clinical presentations in adults: a retrospective study","volume":"17","author":"Sun","year":"2024","journal-title":"Clin Kidney J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.09.048","article-title":"Membranous nephropathy: integrating basic science into improved clinical management","volume":"91","author":"Cattran","year":"2017","journal-title":"Kidney Int"},{"key":"B26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/nejmoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx295","article-title":"Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort","volume":"33","author":"Wang","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1044782","article-title":"Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: a single-centre experience","volume":"14","author":"Chen","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfx105","article-title":"Low-dose rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience","volume":"11","author":"Bagchi","year":"2018","journal-title":"Clin Kidney J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100853","article-title":"Obinutuzumab in refractory membranous nephropathy: a case series","volume":"6","author":"Lin","year":"2024","journal-title":"Kidney Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.0000000000000555","article-title":"Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy","volume":"19","author":"Hu","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/mnh.0b013e32835026ed","article-title":"Obinutuzumab is effective for the treatment of refractory membranous nephropathy","volume":"5","author":"Sethi","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.01.035","article-title":"Obinutuzumab in refractory phospholipase A2 receptor-associated membranous nephropathy with severe CKD","volume":"8","author":"Naik","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.02.444","article-title":"Successful treatment of patients with refractory PLA(2)R-associated membranous nephropathy with obinutuzumab: a report of 3 cases","volume":"76","author":"Klomjit","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab250","article-title":"Membranous nephropathy associated with immunoglobulin G4-related disease successfully treated with obinutuzumab","volume":"15","author":"Ginth\u00f6r","year":"2022","journal-title":"Clin Kidney J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1347880","article-title":"Case report: One case of refractory membranous nephropathy with hypokalemia after rituximab infusion was switched to obinutuzumab without recurrence of hypokalemia","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae230","article-title":"Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy","volume":"40","author":"Xu","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1156470","article-title":"Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01080905","article-title":"Rituximab for idiopathic membranous nephropathy: who can benefit","volume":"1","author":"Ruggenenti","year":"2006","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1825745\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:46:40Z","timestamp":1782452800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1825745\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2026.1825745"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1825745","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"article-number":"1825745"}}